Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)
Conditions
Brief summary
This is a 10-year, longitudinal, observational study of patients with NAFLD/NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, the biospecimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.
Detailed description
Non-alcoholic fatty liver disease (NAFLD) is an excess accumulation of fat in the liver cells. It is associated with obesity, high blood pressure, high cholesterol, and diabetes. Some people with NAFLD only have excess fat in the liver. However, other people may develop a worse form of NAFLD with liver injury and scarring. This form, called non-alcoholic steatohepatitis (NASH), can lead to liver failure, liver cancer, and death. Not much is known about why some people develop NASH and others do not. This study aims to determine and elucidate, through the cooperative effort of a multidisciplinary and multicenter group of collaborators, the etiology, natural history, diagnosis, treatment, and prevention of NAFLD, and in particular its more severe form of NASH and its complications in Chinese subjects.
Interventions
None listed
Sponsors
Humanity and Health Research Centre
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Males or females aged 18 and older; * Adults being managed or treated for NAFL or NASH; * Be able to communicate meaningfully with the Investigator and be legally competent to provide written informed consent.
Exclusion criteria
* Incompetent to understand and/or sign the informed consent; * Ethanol consumption exceeding more than 14 standard beverages per week for males and more than 7 standard beverages per week for female; * Causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, Wilson's disease, viral infections, starvation or parenteral nutrition, among others, and conditions associated with microvesicular steatosis * Diagnosis of liver cirrhosis and/or hepatocellular carcinoma; * Diagnosis of chronic inflammatory disease (i.e. inflammatory bowel disease, rheumatoid arthritis, inflammatory lung disease, severe infectious diseases), other than NAFL/NASH.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of NAFL/NASH in Chinese | up to 10 years | Determine the prevalence of NAFLD/NASH in military beneficiaries ages 18 or above. This will be determined by the % of subjects determined to have NAFLD/NASH in Chinese subjects. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Live imaging analysis | up to 10 years | Transient elastography (FibroScan) and/or MR elastography will provide a measurement of liver stiffness. The liver stiffness metrics will be tabulated for each of the three time points and assessed for change. |
| Exploration, identification and validation of the circulating biomarkers for prediction and diagnosis of NAFL/NASH in Chinese | up to 10 years | Cytokeratin-18 (CK-18), fibrosis-4 (FIB-4), leptin, adiponectin, TNF-alpha, PAI-1, IL-6, MCP-1, retinoids and other potential biomarkers will be determined and analysed. |
| Liver histology analysis | up to 10 years | Liver histology (derived from central reading of liver biopsy at entry, standard of care biopsy done during screening or follow-up) will be examined and scored. |
Countries
Hong Kong
Contacts
CONTACTYudong Wang, PhD
Outcome results
None listed